Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 517

1.

Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial.

Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, Adachi JD.

Bone. 2003 Oct;33(4):522-32.

PMID:
14555255
2.

Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.

Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR, Wong M, Cummings SR; Continuing Outcomes Relevant to Evista (CORE) Investigators.

J Bone Miner Res. 2005 Sep;20(9):1514-24. Epub 2005 May 16.

3.

Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.

Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD.

J Bone Miner Res. 2002 Jan;17(1):1-10.

4.
5.

Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial.

Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA.

J Bone Miner Res. 2008 Dec;23(12):1923-34. doi: 10.1359/jbmr.080710.

6.

Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis.

Maricic M, Adachi JD, Sarkar S, Wu W, Wong M, Harper KD.

Arch Intern Med. 2002 May 27;162(10):1140-3.

PMID:
12020184
7.

Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.

Ensrud KE, Black DM, Palermo L, Bauer DC, Barrett-Connor E, Quandt SA, Thompson DE, Karpf DB.

Arch Intern Med. 1997 Dec 8-22;157(22):2617-24.

PMID:
9531231
8.

Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.

McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J, Kayan K, Beneton M, Jalava T, Pylkkänen L, Kenraali J, Aropuu S, Kanis JA.

J Bone Miner Res. 2004 May;19(5):728-36. Epub 2004 Jan 19.

11.

Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors.

Roux C, Reginster JY, Fechtenbaum J, Kolta S, Sawicki A, Tulassay Z, Luisetto G, Padrino JM, Doyle D, Prince R, Fardellone P, Sorensen OH, Meunier PJ.

J Bone Miner Res. 2006 Apr;21(4):536-42. Epub 2006 Apr 5.

12.

Aging bone and osteoporosis: strategies for preventing fractures in the elderly.

Ettinger MP.

Arch Intern Med. 2003 Oct 13;163(18):2237-46. Review.

PMID:
14557222
14.
15.

Raloxifene: results from the MORE study.

Agnusdei D, Iori N.

J Musculoskelet Neuronal Interact. 2000 Dec;1(2):127-32.

16.

Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older.

Seeman E, Vellas B, Benhamou C, Aquino JP, Semler J, Kaufman JM, Hoszowski K, Varela AR, Fiore C, Brixen K, Reginster JY, Boonen S.

J Bone Miner Res. 2006 Jul;21(7):1113-20.

17.
18.

Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.

Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C.

Arthritis Rheum. 2003 Nov;48(11):3224-9.

19.

Hot flushes, bone mineral density, and fractures in older postmenopausal women.

Huang A, Grady D, Blackwell T, Bauer D.

Obstet Gynecol. 2007 Apr;109(4):841-7.

PMID:
17400844
20.

Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.

Recker RR, Kendler D, Recknor CP, Rooney TW, Lewiecki EM, Utian WH, Cauley JA, Lorraine J, Qu Y, Kulkarni PM, Gaich CL, Wong M, Plouffe L Jr, Stock JL.

Bone. 2007 Apr;40(4):843-51. Epub 2006 Dec 19.

PMID:
17182297

Supplemental Content

Support Center